Immunotherapy drug opens a new era of precision medicine for cancer

In major shift, Pa. to expand hepatitis C treatment for Medicaid patients
June 9, 2017
Hepatitis C: Opioid Epidemic Leads to More Cases
June 12, 2017
Show all

Immunotherapy drug opens a new era of precision medicine for cancer

Genetic mutations of various tumors are increasingly important to identify in cancer treatment.

With little fanfare, the Food and Drug Administration did something this week that it’s never done before: The agency approved a single prescription drug, pembrolizumab (marketed by Merck as Keytruda) for treatment of solid tumors in any organ so long as the malignancy bears a specific genetic signature.

In the fast-moving field of cancer treatment, the FDA’s announcement marks an important milestone, close to two decades in the making. Increasingly, cancer will no longer be identified, categorized and treated by the organ it inhabits, or in which it first gained its foothold. In a shift that is already underway, cancers will be known by — and treated for — the common genetic mutations that nurture and sustain them.

Read full article: Immunotherapy drug opens a new era of precision medicine for cancer – LA Times

Read Full Article: Immunotherapy drug opens a new era of precision medicine for cancer – LA Times

The health and medical information on our website is not intended to take the place of advice or treatment from health care professionals. It is also not intended to substitute for the users’ relationships with their own health care/pharmaceutical providers.

Comments are closed.